Charles Schwab Investment Management Inc. Purchases 22,198 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Charles Schwab Investment Management Inc. boosted its position in Omnicell, Inc. (NASDAQ:OMCL) by 3.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 594,996 shares of the company’s stock after purchasing an additional 22,198 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.29% of Omnicell worth $25,942,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Arizona State Retirement System lifted its stake in Omnicell by 2.9% in the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after purchasing an additional 357 shares during the last quarter. Diversified Trust Co lifted its stake in Omnicell by 3.3% in the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock worth $416,000 after purchasing an additional 494 shares during the last quarter. GAMMA Investing LLC lifted its stake in Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock worth $625,000 after purchasing an additional 600 shares during the last quarter. Finally, Curi RMB Capital LLC lifted its stake in Omnicell by 0.7% in the third quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock worth $3,872,000 after purchasing an additional 651 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on OMCL. Craig Hallum raised their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Barclays raised their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Wednesday, November 27th. Benchmark reaffirmed a “buy” rating and set a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Finally, Bank of America reaffirmed a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $52.00.

Omnicell Stock Down 2.1 %

Shares of OMCL stock opened at $45.91 on Thursday. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -117.71, a PEG ratio of 36.17 and a beta of 0.77. The company’s 50 day moving average is $44.77 and its 200 day moving average is $38.33. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.